US Patent 8,846,066: Scope, Claims, Expiration, and Deoxycholic Acid Patent Landscape

US Patent 8,846,066 protects injected deoxycholate compositions for reducing localized adipose tissue, including lipomas, when the composition excludes phosphatidylcholine. The patent is a method-of-treatment patent rather than a broad composition patent. Its commercial relevance is tied to deoxycholic acid products such as Kybella in the United States and Belkyra in other markets. AbbVie, through its acquisition of Kythera Biopharmaceuticals, is the principal commercial rights holder associated with the estate.

The broadest independent claims require four elements: a benign isolated adipose collection or lipoma, injection into that tissue, an effective amount of deoxycholate, and administration in the absence of phosphatidylcholine. The dependent claims narrow the technology to solutions, 1% to 5% concentrations, repeated administration, and sodium deoxycholate.

What does US Patent 8,846,066 protect?

The patent protects a treatment method using injected deoxycholate without phosphatidylcholine to reduce localized adipose tissue.

Claim	Protected subject matter	Practical scope
1	Injection of deoxycholate without phosphatidylcholine into a benign, isolated adipose tissue collection	Broad method claim for localized adipose reduction
2	Injection of deoxycholate without phosphatidylcholine into a lipoma	Specific lipoma-treatment claim
3	Claim 1 where the composition is a solution	Excludes non-solution implementations from this dependent claim
4	Solution containing 1% to 5% deoxycholate	Concentration-range claim
5	Solution containing 1% deoxycholate	Specific concentration claim
6	More than one administration	Repeated-treatment claim
7	Deoxycholate is sodium deoxycholate	Salt-specific claim

The independent claims use “comprising,” which generally permits additional ingredients unless those ingredients contradict an express claim limitation. The express exclusion of phosphatidylcholine is therefore central. A formulation can contain buffers, preservatives, water, salts, pH adjusters, or other excipients, but a composition containing phosphatidylcholine would create a substantial non-infringement position against these particular claims.

How should the independent claims be construed?

Claim 1: benign isolated adipose tissue

Claim 1 has a tissue-based limitation. It does not cover every use of deoxycholate in the body. The target must be a “benign, isolated collection of adipose tissue,” and the treatment must reduce its size.

The claim is directed to localized deposits rather than systemic obesity treatment. Examples likely within its conceptual scope include:

Localized subcutaneous fat deposits
Discrete benign adipose masses
Small, isolated fatty collections
Localized deposits treated by direct injection

The requirement that the tissue be benign and isolated creates potential claim-construction disputes. A manufacturer could argue that diffuse abdominal fat, generalized obesity, or non-discrete adipose tissue does not satisfy the limitation.

Claim 2: lipoma treatment

Claim 2 is narrower in target but potentially clearer in application. A lipoma is a benign tumor composed primarily of mature adipose tissue. The claim requires injection into the lipoma and reduction in its size.

A product used exclusively for cosmetic submental fat may not literally practice claim 2 because submental fullness is not necessarily a lipoma. Claim 1 may still be relevant if the treated tissue is characterized as a benign, isolated adipose collection.

Claim 2 does not require a particular concentration, salt, dosage volume, number of injections, or treatment interval. Those limitations appear only in dependent claims or would be assessed under the “effective amount” and “conditions wherein” language.

What formulations are protected by US 8,846,066?

The patent does not claim a deoxycholate composition in the abstract. It claims use of the composition by injection.

A potentially infringing formulation would generally have the following characteristics:

Deoxycholate as an active ingredient.
No phosphatidylcholine.
Injection into a localized benign adipose deposit or lipoma.
An amount sufficient to reduce tissue size.
A solution, where claims 3 through 5 are asserted.
Sodium deoxycholate, where claim 7 is asserted.

The patent does not require that deoxycholate be the only active ingredient. “Comprising” permits other components, subject to the exclusion of phosphatidylcholine.

Concentration limitations

Claims 4 and 5 provide meaningful fallback positions:

Claim 4 covers 1% through 5%, including the endpoints.
Claim 5 covers 1%.
A solution below 1% or above 5% would not literally satisfy claims 4 or 5, but could still fall within claim 1 or claim 3 if the other limitations are met.
A non-solution formulation would not satisfy claim 3, but may still be evaluated against claim 1.

The concentration range is narrower than the independent method claims. A competitor could attempt a design-around using a concentration outside 1% to 5%, but that strategy would not address the broader claims.

Sodium deoxycholate

Claim 7 narrows the compound to sodium deoxycholate. This is commercially important because sodium deoxycholate is the active ingredient identified for Kybella and Belkyra. A competitor using another deoxycholate salt could potentially avoid claim 7 while remaining exposed to claims 1 through 6, depending on claim construction and the product’s conversion to deoxycholate in use.

When does US Patent 8,846,066 lose exclusivity?

Public patent records identify US 8,846,066 as issued on September 30, 2014. Its effective expiration is generally assessed under the 20-year patent-term rule measured from the earliest relevant nonprovisional filing, adjusted for patent-term adjustment and any applicable extensions.

The patent estate associated with deoxycholic acid products has been reported with expiration dates extending into the 2026-2027 period, depending on the specific patent, patent-term adjustment, and regulatory listing. Patent 8,846,066 should not be treated as the only exclusivity barrier for Kybella. Later-issued continuation and formulation patents may carry different expiration dates.

Exclusivity layer	Relevance
US 8,846,066	Core method claims for injected deoxycholate without phosphatidylcholine
Later continuation patents	May claim narrower treatment methods, dosing, or formulations
FDA regulatory exclusivity	Separate from patent term and tied to the approved NDA
Orphan-drug exclusivity	Not generally the principal Kybella barrier
Patent-term adjustment	Can extend the enforceable patent term beyond the basic 20-year calculation

FDA approval of Kybella occurred on April 29, 2015. The product received approval for improvement in the appearance of moderate to severe submental convexity associated with submental fat in adults, not for lipoma treatment. FDA approval therefore does not establish that every claim in the patent is covered by the approved label. (U.S. Food and Drug Administration, 2015)

What is the Orange Book status of Kybella and related patents?

Kybella is an approved prescription drug listed in the FDA Orange Book under deoxycholic acid injection. Orange Book listings may include patents that claim the drug substance, formulation, method of use, or approved conditions of use.

The commercial relevance of US 8,846,066 depends on whether and when the patent is listed against the approved Kybella NDA. A method patent that covers lipoma treatment may have weaker Orange Book relevance if the approved label is limited to submental fat. By contrast, a patent claiming treatment of submental adipose tissue, administration parameters, or the approved formulation is more likely to affect an ANDA applicant’s certification and launch timing.

An ANDA applicant must address listed patents through a Paragraph I, II, III, or IV certification. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or will not be infringed. The patent listing, not the full patent family alone, determines whether a Paragraph IV filing triggers the statutory litigation framework under the Hatch-Waxman Act.

Which companies are challenging the deoxycholic acid patent estate?

The principal competitive threat is expected to come from generic manufacturers pursuing an ANDA for deoxycholic acid injection. Potential challengers would include large injectable-drug manufacturers and companies with dermatology or aesthetic medicine portfolios.

A definitive assessment of current Paragraph IV challengers and active district-court cases requires the current FDA Orange Book patent listing, ANDA litigation records, and docket review. The claim text alone does not establish whether a particular company has filed a Paragraph IV certification or whether litigation is pending.

The relevant legal issues for a challenger would likely include:

Whether the accused product is administered for a claimed indication.
Whether the target tissue is a benign isolated adipose collection.
Whether a lipoma limitation is satisfied.
Whether the product contains phosphatidylcholine.
Whether the accused treatment reduces tissue size.
Whether the asserted claims are anticipated or obvious.
Whether the claims are enabled across the full scope.
Whether the patent is enforceable after any prosecution-history or inequitable-conduct challenge.

What patent litigation affects US 8,846,066?

The strongest litigation exposure would arise from an ANDA for a product labeled for submental fat reduction or another localized adipose indication. A generic applicant could challenge the patent directly through a Paragraph IV certification or indirectly by pursuing a label that omits the patented use.

The patent’s method format creates a distinction between product approval and induced infringement. A generic manufacturer may seek a “skinny label” excluding patented uses. That strategy is more effective where the approved product has multiple uses and the omitted use is separable. It is less effective if the remaining label necessarily encourages practice of the asserted claims.

For this patent, a skinny-label defense could be stronger against the lipoma claim than against a broader adipose-treatment claim, because Kybella’s approved use concerns submental fat rather than lipomas. The analysis would depend on the exact Orange Book listing, label language, promotional materials, physician prescribing behavior, and evidence of induced infringement.

How does US 8,846,066 compare with later Kybella patents?

US 8,846,066 is best viewed as an early platform patent. It captures the central concept of injecting deoxycholate without phosphatidylcholine into localized adipose tissue.

Later patents in the estate may be narrower but commercially important because they can cover:

Specific injection techniques
Treatment of submental fat
Dosing schedules
Injection volumes
Concentration and pH
Stabilized formulations
Manufacturing processes
Packaging or delivery systems
Additional cosmetic indications

Patent category	Typical protection	Design-around difficulty
Core treatment method	Deoxycholate injection into localized fat	Moderate to high if the same indication is used
Lipoma method	Direct treatment of lipomas	Lower if product label excludes lipomas
Concentration claim	1% to 5% solution	Moderate
Salt-specific claim	Sodium deoxycholate	Moderate
Formulation claim	Excipient, pH, stability, or impurity profile	Variable
Administration claim	Injection pattern or dosing schedule	Variable
Manufacturing claim	Production and purification process	High if process is proprietary

What is the regulatory status of deoxycholic acid injection?

Kybella is FDA-approved for adults with moderate to severe submental convexity associated with submental fat. The active ingredient is deoxycholic acid, a naturally occurring bile acid that disrupts adipocyte membranes when injected into localized adipose tissue.

The approved label does not establish approval for lipoma treatment. Use of Kybella for lipomas would generally be outside the FDA-approved indication. That regulatory distinction matters to patent analysis because claim 2 specifically targets lipomas, while the commercial product’s principal approved use is submental fat reduction.

Outside the United States, Belkyra is the principal corresponding product name. Regulatory approval, patent scope, and labeling differ by jurisdiction.

What licensing deals support the patent estate?

Kythera developed Kybella and held rights associated with the injectable deoxycholate technology before Allergan acquired Kythera in 2016. Allergan subsequently became part of AbbVie in 2020. University-originated research and licensing arrangements were associated with the development of injectable adipolysis technology.

The transaction chain is commercially relevant:

Period	Corporate event
Development period	Kythera develops injectable deoxycholate technology
2014	US 8,846,066 issues
2015	FDA approves Kybella
2016	Allergan acquires Kythera
2020	AbbVie completes acquisition of Allergan

The relevant patent-holder analysis should therefore distinguish the original named assignee from the current commercial owner or exclusive licensee. Patent assignments and security interests control legal ownership, while licensing agreements may control enforcement and commercialization rights.

How strong is the patent estate for deoxycholate injection?

US 8,846,066 has meaningful but limited strength.

Strengths

It covers the central therapeutic concept rather than a narrow manufacturing step.
It expressly covers injection into lipomas.
It does not require a specific brand, device, or formulation excipient.
Claim 1 is broader than the 1% to 5% concentration claims.
The absence of phosphatidylcholine distinguishes the claimed approach from older phosphatidylcholine/deoxycholate formulations.

Vulnerabilities

The claims are method claims and require actual treatment conduct.
The benign and isolated tissue limitations invite factual disputes.
The patent does not broadly claim every deoxycholate composition.
The lipoma claim may not map cleanly onto Kybella’s approved submental-fat indication.
Prior-art challenges may focus on earlier use of bile salts or deoxycholate for adipocyte disruption.
A competitor may seek a non-infringing indication, concentration, formulation, or administration protocol.

The estate is stronger when asserted against a product labeled for direct injection into localized adipose deposits and weaker when asserted against a product directed to diffuse fat, a non-adipose indication, or a formulation containing phosphatidylcholine.

What generic launch scenarios exist?

Scenario 1: Patent challenge with litigation stay

A Paragraph IV filing could trigger patent litigation and a statutory stay of ANDA approval for up to 30 months, subject to court and regulatory events. Launch would depend on the outcome, settlement terms, or expiration of the stay.

Scenario 2: Paragraph III certification

An applicant could acknowledge the patent and defer approval until the relevant patent expiration date. This produces a delayed but lower-litigation-risk launch.

Scenario 3: Skinny label

A generic applicant could omit lipoma or other patented uses. The commercial value of that strategy depends on whether the remaining label still induces treatment of the claimed tissue.

Scenario 4: Non-infringing formulation or indication

A competitor could use a different salt, concentration, delivery protocol, or target tissue. This approach must account for the broader independent claims, not only the dependent claims.

What revenue exposure is associated with the patent?

Kybella is a branded aesthetic product whose revenue exposure is concentrated in the United States because the product lacks the broad chronic-use volume of systemic therapies. Patent expiry could affect price, payer coverage, clinic purchasing, and physician switching.

The commercial impact of generic entry would depend on:

Number of approved ANDAs
Availability of prefilled or ready-to-use presentations
Injectable manufacturing capacity
FDA inspection and supply-chain requirements
Physician familiarity with the branded product
Direct-to-consumer marketing
Reimbursement and cash-pay economics
Whether generic entrants can use the same primary indication

AbbVie’s public filings should be used for product-level revenue figures because Kybella revenue may be reported within broader aesthetics or neuroscience categories rather than as a standalone line item. (AbbVie Inc., 2024)

Key Takeaways

US 8,846,066 is a method patent covering injected deoxycholate without phosphatidylcholine for reducing localized benign adipose tissue.
Claim 2 specifically covers injection into a lipoma.
Claims 3 through 7 add solution, concentration, repeated-treatment, and sodium-deoxycholate limitations.
The patent does not broadly claim every deoxycholate composition.
The strongest infringement case would involve direct injection into localized adipose tissue under a label that encourages the claimed use.
A product containing phosphatidylcholine would have a strong non-infringement position against these claims.
Kybella was FDA-approved in 2015 for adult submental fat, not lipoma treatment.
Later Kybella patents may extend the commercial exclusivity period beyond the expiration of US 8,846,066.
Generic risk depends on Orange Book listings, Paragraph IV certifications, litigation, skinny-label strategy, and the enforceability of continuation patents.
The patent estate is commercially relevant but vulnerable to claim-construction, prior-art, and induced-infringement challenges.

FAQs

Does US 8,846,066 cover Kybella for double-chin fat?

Potentially, depending on the claim interpretation and the exact patent listing. The patent covers treatment of a benign isolated adipose collection, while Kybella is approved for submental fat. Later patents may more directly cover the approved submental indication.

Does US 8,846,066 cover phosphatidylcholine and deoxycholate mixtures?

No. The claims expressly require administration of deoxycholate in the absence of phosphatidylcholine. A formulation containing phosphatidylcholine would not satisfy that express limitation.

Is lipoma treatment with deoxycholic acid FDA-approved?

No. Kybella’s FDA-approved indication is adult submental fat reduction. Lipoma treatment is not the approved indication identified in the Kybella label.

Can a generic avoid US 8,846,066 by using a concentration below 1%?

That could avoid the specific concentration claims in claims 4 and 5, but it would not automatically avoid claim 1 or claim 3. The broader claims do not state a numerical concentration.

Does the patent cover non-sodium deoxycholate?

Claims 1 through 6 are not limited to sodium deoxycholate. Claim 7 is. A non-sodium deoxycholate product could remain exposed to the broader claims if the other limitations are satisfied.

References

AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investors.abbvie.com
Kythera Biopharmaceuticals, Inc. (2015). Kybella prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2015, April 29). FDA approves treatment to improve appearance of moderate to severe fat below the chin. https://www.fda.gov
U.S. Patent and Trademark Office. (2014). United States Patent No. 8,846,066, treatment of adipose tissue using deoxycholic acid. https://patents.google.com/patent/US8846066
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1758590	⤷ Start Trial	PA2017006	Lithuania	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	300907	Netherlands	⤷ Start Trial
European Patent Office	1758590	⤷ Start Trial	CA 2017 00067	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,846,066

Summary for Patent: 8,846,066